UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Agbele, K. K., Oriogun, P. K., Seluwa, A. G., & Aruleba, K. D. (2015). Towards a model for enhancing ICT4 development and information security in healthcare system. 2015 IEEE International Symposium on Technology and Society (ISTAS), 1–6. https://doi.org/10.1109/ISTAS.2015.7439404

Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi-Rad, J., Calina, D., & Cho, W. C. (2022). Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell International, 22(1), 284. https://doi.org/10.1186/s12935-022-02706-8

Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M. (2023). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases, 10(4), 1367–1401. https://doi.org/10.1016/j.gendis.2022.02.007

Aruleba, R. T., Adekiya, T. A., Ayawei, N., Obaido, G., Aruleba, K., Mienye, I. D., Aruleba, I., & Ogbuokiri, B. (2022). COVID-19 Diagnosis: A Review of Rapid Antigen, RT-PCR and Artificial Intelligence Methods. Bioengineering, 9(4), 153. https://doi.org/10.3390/bioengineering9040153

Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., Dukart, G., & Sherman, M. L. (2004). Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. Journal of Clinical Oncology, 22(5), 909–918. https://doi.org/10.1200/JCO.2004.08.185

Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., Wilner, K. D., Lockerman, E. L., Khan, T. M., Mahmood, S., Gainor, J. F., Digumarthy, S. R., Stone, J. R., Mino-Kenudson, M., Christensen, J. G., … Shaw, A. T. (2013). Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1. New England Journal of Medicine, 368(25), 2395–2401. https://doi.org/10.1056/NEJMoa1215530

Awale, M., & Reymond, J.-L. (2019). Web-Based Tools for Polypharmacology Prediction. In S. Ziegler & H. Waldmann (Eds.), Systems Chemical Biology (Vol. 1888, pp. 255–272). Springer New York. https://doi.org/10.1007/978-1-4939-8891-4_15

Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016). Architecture of human mTOR complex 1. Science (New York, N.Y.), 351(6268), 48–52. https://doi.org/10.1126/science.aaa3870

B, A., & Kamala, G. R. (2025). Principles and Applications of Molecular Docking in Drug Discovery and Development: Review Article. Journal of Pharma Insights and Research, 3(4), 140–151. https://doi.org/10.69613/29zcv966

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Baell, J. B., & Holloway, G. A. (2010). New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740. https://doi.org/10.1021/jm901137j

Baell, J. B., & Nissink, J. W. M. (2018). Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations. ACS Chemical Biology, 13(1), 36–44. https://doi.org/10.1021/acschembio.7b00903

Bajusz, D., Rácz, A., & Héberger, K. (2015). Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? Journal of Cheminformatics, 7(1), 20. https://doi.org/10.1186/s13321-015-0069-3

Balala, K., Ancheta, M., Arriola, G., Balanon, T., & Aban, J. (2024). Different stages, grades and types of cancer: A systematic review. https://doi.org/10.13140/RG.2.2.15612.35201

Baldi, N., Giorgetti, A., Polidoro, A., Palladino, M., Giovannetti, I., Arcidiacono, G., & Citti, P. (2023). A Supervised Machine Learning Model for Regression to Predict Melt Pool Formation and Morphology in Laser Powder Bed Fusion. Applied Sciences, 14(1), 328. https://doi.org/10.3390/app14010328

Ballante, F., Kooistra, A. J., Kampen, S., de Graaf, C., & Carlsson, J. (2021). Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You? Pharmacological Reviews, 73(4), 527–565. https://doi.org/10.1124/pharmrev.120.000246

Ballou, L. M., & Lin, R. Z. (2008). Rapamycin and mTOR kinase inhibitors. Journal of Chemical Biology, 1(1–4), 27–36. https://doi.org/10.1007/s12154-008-0003-5

Bento, A. P., Hersey, A., Félix, E., Landrum, G., Gaulton, A., Atkinson, F., Bellis, L. J., De Veij, M., & Leach, A. R. (2020). An open source chemical structure curation pipeline using RDKit. Journal of Cheminformatics, 12(1), 51. https://doi.org/10.1186/s13321-020-00456-1

Berthold, M. R., Cebron, N., Dill, F., Fatta, G. D., Gabriel, T. R., Georg, F., Meinl, T., Ohl, P., Sieb, C., & Wiswedel, B. (n.d.). Knime: The Konstanz Information Miner.

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834

Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008). Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. ChemMedChem, 3(3), 435–444. https://doi.org/10.1002/cmdc.200700139

Brown, J. S., Amend, S. R., Austin, R. H., Gatenby, R. A., Hammarlund, E. U., & Pienta, K. J. (2023). Updating the Definition of Cancer. Molecular Cancer Research, 21(11), 1142–1147. https://doi.org/10.1158/1541-7786.MCR-23-0411

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Bruce, J. L. (2025). An Overview of Supervised Machine Learning in Drug Discovery, PK/PD Modeling and Precision Pharmacogenomics. Medical & Clinical Case Reports Journal, 3(4), 1439–1445. https://doi.org/10.51219/MCCRJ/Julian-Lloyd-Bruce/406

Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A., Kassouf, W., Mitchell, T., Montironi, R., O'Brien, T., Panebianco, V., Scelo, G., Shuch, B., Van Poppel, H., Blosser, C. D., & Psutka, S. P. (2022). Epidemiology of Renal Cell Carcinoma: 2022 Update. European Urology, 82(5), 529–542. https://doi.org/10.1016/j.eururo.2022.08.019

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics—PMC. (n.d.). Retrieved December 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC10310991/

Capecchi, A., Probst, D., & Reymond, J.-L. (2020). One molecular fingerprint to rule them all: Drugs, biomolecules, and the metabolome. Journal of Cheminformatics, 12(1), 43. https://doi.org/10.1186/s13321-020-00445-4

Carlsson, J., & Luttens, A. (2024). Structure-based virtual screening of vast chemical space as a starting point for drug discovery. Current Opinion in Structural Biology, 87, 102829. https://doi.org/10.1016/j.sbi.2024.102829

Carpenter, K. A., & Huang, X. (2018). Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review. Current Pharmaceutical Design, 24(28), 3347–3358. https://doi.org/10.2174/1381612824666180607124038

Chabner, B. A., & Roberts, T. G. (2005). Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65–72. https://doi.org/10.1038/nrc1529

ChEMBL Database in 2023: A drug discovery platform spanning multiple bioactivity data types and time periods | Nucleic Acids Research | Oxford Academic. (n.d.-a). Retrieved December 15, 2025, from https://academic.oup.com/nar/article/52/D1/D1180/7337608

ChEMBL Database in 2023: A drug discovery platform spanning multiple bioactivity data types and time periods | Nucleic Acids Research | Oxford Academic. (n.d.-b). Retrieved December 28, 2025, from https://academic.oup.com/nar/article/52/D1/D1180/7337608

Chemotherapy and the war on cancer | Nature Reviews Cancer. (n.d.-a). Retrieved December 15, 2025, from https://www.nature.com/articles/nrc1529

Chemotherapy and the war on cancer | Nature Reviews Cancer. (n.d.-b). Retrieved December 28, 2025, from https://www.nature.com/articles/nrc1529

Chen, Z., Yang, H., Li, Z., Xia, Q., & Nie, Y. (2019). Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling. Biochemical and Biophysical Research Communications, 516(3), 726–732. https://doi.org/10.1016/j.bbrc.2019.06.127

Cho, B. C., Chiu, C.-H., Massarelli, E., Buchschacher, G. L., Goto, K., Overbeck, T. R., Loong, H. H. F., Chee, C. E., Garrido, P., Dong, X., Fan, Y., Lu, S., Schwemmers, S., Bordogna, W., Zeuner, H., Osborne, S., & John, T. (2024). Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer, 188, 107442. https://doi.org/10.1016/j.lungcan.2023.107442

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996). Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP. Science, 273(5272), 239–242. https://doi.org/10.1126/science.273.5272.239

Chuang, K. V., Gunsalus, L. M., & Keiser, M. J. (2020). Learning Molecular Representations for Medicinal Chemistry: Miniperspective. Journal of Medicinal Chemistry, 63(16), 8705–8722. https://doi.org/10.1021/acs.jmedchem.0c00385

Cinque, A., Minnei, R., Floris, M., & Trevisani, F. (2022). The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma? Cancers, 14(21), 5352. https://doi.org/10.3390/cancers14215352

Ciołczyk-Wierzbicka, D., Zarzycka, M., Placha, W., Zemanek, G., & Wierzbicki, K. (2024). Treatment of Melanoma Cells with Chloroquine and Everolimus Activates the Apoptosis Process and Alters Lipid Redistribution. International Journal of Molecular Sciences, 25(22), 12278. https://doi.org/10.3390/ijms252212278

Cirillo, L., Innocenti, S., & Becherucci, F. (2024). Global epidemiology of kidney cancer. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 39(6), 920–928. https://doi.org/10.1093/ndt/gfae036

Cohen-Addad, V., Kanade, V., Mallmann-Trenn, F., & Mathieu, C. (2017). Hierarchical Clustering: Objective Functions and Algorithms (Version 1). arXiv. https://doi.org/10.48550/ARXIV.1704.02147

Das, A. P., Mathur, P., & Agarwal, S. M. (2024). Machine Learning, Molecular Docking, and Dynamics-Based Computational Identification of Potential Inhibitors against Lung Cancer. ACS Omega, 9(4), 4528–4539. https://doi.org/10.1021/acsomega.3c07338

Diéguez-Santana, K., Casañola-Martin, G. M., Torres, R., Rasulev, B., Green, J. R., & González-Díaz, H. (2022). Machine Learning Study of Metabolic Networks vs ChEMBL Data of Antibacterial Compounds. Molecular Pharmaceutics, 19(7), 2151–2163. https://doi.org/10.1021/acs.molpharmaceut.2c00029

Diller, D. J., & Hobbs, D. W. (2004). Deriving knowledge through data mining high-throughput screening data. Journal of Medicinal Chemistry, 47(25), 6373–6383. https://doi.org/10.1021/jm049902r

Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., De Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., Seto, T., Cho, B. C., Patel, M. R., Chiu, C.-H., John, T., Goto, K., Karapetis, C. S., Arkenau, H.-T., Kim, S.-W., … Doebele, R. C. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1–2 trials. The Lancet Oncology, 21(2), 261–270. https://doi.org/10.1016/S1470-2045(19)30690-4

Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., Doebele, R., Giannetta, L., Cerea, G., Marrapese, G., Schirru, M., Amatu, A., Bencardino, K., Palmeri, L.,

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Sartore-Bianchi, A., … De Braud, F. G. (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 7(4), 400–409. https://doi.org/10.1158/2159-8290.CD-16-1237

Engl, T., Rutz, J., Maxeiner, S., Fanguen, S., Juengel, E., Koschade, S., Roos, F., Khoder, W., Tsaur, I., & Blaheta, R. A. (2018). Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro. Oncotarget, 9(27), 18747–18759. https://doi.org/10.18632/oncotarget.24650

Filho, A. M., Laversanne, M., Ferlay, J., Colombet, M., Piñeros, M., Znaor, A., Parkin, D. M., Soerjomataram, I., & Bray, F. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. International Journal of Cancer, 156(7), 1336–1346. https://doi.org/10.1002/ijc.35278

Formisano, L., Napolitano, F., Rosa, R., D'Amato, V., Servetto, A., Marciano, R., De Placido, P., Bianco, C., & Bianco, R. (2020). Mechanisms of resistance to mTOR inhibitors. Critical Reviews in Oncology/Hematology, 147, 102886. https://doi.org/10.1016/j.critrevonc.2020.102886

Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., & Overington, J. P. (2012). ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Research, 40(D1), D1100–D1107. https://doi.org/10.1093/nar/gkr777

Ghosh, P., Kumar, A., & Singh, S. K. (2025). COX -2 Inhibitor Prediction With KNIME: A Codeless Automated Machine Learning-Based Virtual Screening Workflow. Journal of Computational Chemistry, 46(2), e70030. https://doi.org/10.1002/jcc.70030

Gibbons, R. P., Montie, J. E., Correa, R. J., & Tate Mason, J. (1976). Manifestations of renal cell carcinoma. Urology, 8(3), 201–206. https://doi.org/10.1016/0090-4295(76)90366-6

Grosjean, H., & Biggin, P. C. (2026). Developments and challenges in hit progression within fragment-based drug discovery. Nature Communications, 17(1), 2226. https://doi.org/10.1038/s41467-026-68941-z

Halgren, T. A. (1996). Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry, 17(5–6), 490–519. https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6%253C490::AID-JCC1%253E3.0.CO;2-P

Hansen, P., Jaumard, B., & Sanlaville, E. (1994). Partitioning Problems in Cluster Analysis: A Review of Mathematical Programming Approaches. In E. Diday, Y. Lechevallier, M. Schader, P. Bertrand, & B. Burtschy (Eds.), New Approaches in Classification and Data Analysis (pp. 228–240). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-51175-2_26

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hassan, B., Akcakanat, A., Holder, A. M., & Meric-Bernstam, F. (2013). Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surgical Oncology Clinics of North America, 22(4), 641–664. https://doi.org/10.1016/j.soc.2013.06.008

Heaton, J. (2018). Ian Goodfellow, Yoshua Bengio, and Aaron Courville: Deep learning: The MIT Press, 2016, 800 pp, ISBN: 0262035618. Genetic Programming and Evolvable Machines, 19(1–2), 305–307. https://doi.org/10.1007/s10710-017-9314-z

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4(12), 988–1004. https://doi.org/10.1038/nrd1902

Hoy, S. M. (2020). Tazemetostat: First Approval. Drugs, 80(5), 513–521. https://doi.org/10.1007/s40265-020-01288-x

Huang, S.-Y., Grinter, S. Z., & Zou, X. (2010). Scoring functions and their evaluation methods for protein–ligand docking: Recent advances and future directions. Physical Chemistry Chemical Physics, 12(40), 12899. https://doi.org/10.1039/c0cp00151a

Irwin, J. J., & Shoichet, B. K. (2005). ZINC − A Free Database of Commercially Available Compounds for Virtual Screening. Journal of Chemical Information and Modeling, 45(1), 177–182. https://doi.org/10.1021/ci049714+

Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell, 127(1), 125–137. https://doi.org/10.1016/j.cell.2006.08.033

Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010). mTOR regulation of autophagy. FEBS Letters, 584(7), 1287–1295. https://doi.org/10.1016/j.febslet.2010.01.017

Kim, L. C., Cook, R. S., & Chen, J. (2017). mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene, 36(16), 2191–2201. https://doi.org/10.1038/onc.2016.363

Kim, L. H., Doan, P., He, Y., Lau, H. M., Pleass, H., & Patel, M. I. (2021). A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes. Journal of Urology, 205(2), 346–355. https://doi.org/10.1097/JU.0000000000001377

Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. https://doi.org/10.1038/nrd1549

Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., Ho, T. H., Song, J., Pignon, J.-C., Barrios, P. M., Michaelson, M. D., Van Allen, E., Krajewski, K. M., Porta, C., Pal, S., … Signoretti, S. (2016). Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research: An Official Journal of the American Association for

UNIVERSITAS GADJAH MADA
Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Cancer Research, 22(10), 2445–2452. https://doi.org/10.1158/1078-0432.CCR-15-2631

Kwitkowski, V. E., Prowell, T. M., Ibrahim, A., Farrell, A. T., Justice, R., Mitchell, S. S., Sridhara, R., & Pazdur, R. (2010). FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma. The Oncologist, 15(4), 428–435. https://doi.org/10.1634/theoncologist.2009-0178

Laboratoire de Technologie Industrielle et de l'Information, Faculté de Technologie, Université de Bejaia, 06000 Bejaia, Algeria, Oubelaid, A., Faculty of Artificial Intelligence, Kafrelsheikh University, Kafrelsheikh, Egypt, Shams, M. Y., Department of System Programming, South Ural State University, 454080 Chelyabinsk, Russia, & Abotaleb, M. (2022). Energy Efficiency Modeling Using Whale Optimization Algorithm and Ensemble Model. Journal of Artificial Intelligence and Metaheuristics, 2(1), 27–35. https://doi.org/10.54216/JAIM.020103

Ladurner, M., Lindner, A. K., Rehder, P., & Tulchiner, G. (2024). The influence of sex hormones on renal cell carcinoma. Therapeutic Advances in Medical Oncology, 16, 17588359241269664. https://doi.org/10.1177/17588359241269664

Lambev, M., Dimitrova, D., & Mihaylova, S. (2025). Machine Learning-Based Prediction of Rule Violations for Drug-Likeness Assessment in Peptide Molecules Using Random Forest Models. International Journal of Molecular Sciences, 26(17), 8407. https://doi.org/10.3390/ijms26178407

Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell, 149(2), 274–293. https://doi.org/10.1016/j.cell.2012.03.017

Leach, A. R. (2001). Molecular modelling: Principles and applications (2. ed., 12. [Dr.]). Pearson/Prentice Hall.

Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases—Brenk—2008—ChemMedChem—Wiley Online Library. (n.d.). Retrieved December 28, 2025, from https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.200700139

Liesen, M. P., & Vilseck, J. Z. (2024). Superimposing Ligands with a Ligand Overlay as an Alternate Topology Model for λ-Dynamics-Based Calculations. The Journal of Physical Chemistry B, 128(46), 11359–11368. https://doi.org/10.1021/acs.jpcb.4c04805

Lin, S.-K. (2000). Pharmacophore Perception, Development and Use in Drug Design. Edited by Osman F. Güner. Molecules, 5(7), 987–989. https://doi.org/10.3390/50700987

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/s0169-409x(00)00129-0

Lobanovska, M., & Pilla, G. (2017). Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future? The Yale Journal of Biology and Medicine, 90(1), 135.

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Molecular Cell, 10(3), 457–468. https://doi.org/10.1016/s1097-2765(02)00636-6

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017). Targeting Metabolism for Cancer Therapy. Cell Chemical Biology, 24(9), 1161–1180. https://doi.org/10.1016/j.chembiol.2017.08.028

Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002). Do Structurally Similar Molecules Have Similar Biological Activity? Journal of Medicinal Chemistry, 45(19), 4350–4358. https://doi.org/10.1021/jm020155c

Medina-Rico, M., López-Ramos, H., Lobo, M., Romo, J., & Guillermo Prada, J. (2017). Epidemiology of renal cancer in developing countries: Review of the literature. Canadian Urological Association Journal, 12(3), E154-62. https://doi.org/10.5489/cuaj.4464

Meijer, A. J., Lorin, S., Blommaart, E. F., & Codogno, P. (2015). Regulation of autophagy by amino acids and MTOR-dependent signal transduction. Amino Acids, 47(10), 2037–2063. https://doi.org/10.1007/s00726-014-1765-4

Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. Current Computer Aided-Drug Design, 7(2), 146–157. https://doi.org/10.2174/157340911795677602

Mishra, N., & Basu, A. (2013). Exploring Different Virtual Screening Strategies for Acetylcholinesterase Inhibitors. BioMed Research International, 2013, 1–8. https://doi.org/10.1155/2013/236850

Moosburner, M., Alibegovic, L., Hasselmann, K., Gaiderov, A., Hildebrand, J., Philippou-Massier, J., Blum, H., Fischer, L., Dreyling, M., & Silkenstedt, E. (2023). Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus. Hematological Oncology, 41(5), 858–868. https://doi.org/10.1002/hon.3194

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256

Mossmann, D., Park, S., & Hall, M. N. (2018). mTOR signalling and cellular metabolism are mutual determinants in cancer. Nature Reviews. Cancer, 18(12), 744–757. https://doi.org/10.1038/s41568-018-0074-8

Muhammed, M. T., & Aki-Yalcin, E. (2024). Molecular Docking: Principles, Advances, and Its Applications in DrugDiscovery. Letters in Drug Design & Discovery, 21(3), 480–495. https://doi.org/10.2174/1570180819666220922103109

Naeem, S., Ali, A., Anam, S., & Ahmed, M. M. (2023). An Unsupervised Machine Learning Algorithms: Comprehensive Review. International Journal of

UNIVERSITAS GADJAH MADA
Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Computing and Digital Systems, 13(1), 911–921. https://doi.org/10.12785/ijcds/130172

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019 | Journal of Natural Products. (n.d.). Retrieved December 16, 2025, from https://pubs.acs.org/doi/10.1021/acs.jnatprod.9b01285

Naveja, J. J., Rico-Hidalgo, M. P., & Medina-Franco, J. L. (2018). Analysis of a large food chemical database: Chemical space, diversity, and complexity. F1000Research, 7, 993. https://doi.org/10.12688/f1000research.15440.2

Newman, D. J., & Cragg, G. M. (2020). Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285

Novel Points of Attack for Targeted Cancer Therapy—Røsland—2015—Basic & Clinical Pharmacology & Toxicology—Wiley Online Library. (n.d.). Retrieved December 28, 2025, from https://onlinelibrary.wiley.com/doi/10.1111/bcpt.12313

Obaido, G., Mienye, I. D., Egbelowo, O. F., Emmanuel, I. D., Ogunleye, A., Ogbuokiri, B., Mienye, P., & Aruleba, K. (2024). Supervised machine learning in drug discovery and development: Algorithms, applications, challenges, and prospects. Machine Learning with Applications, 17, 100576. https://doi.org/10.1016/j.mlwa.2024.100576

Osman, H. M., & Tuncbilek, M. (2022). Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors. Current Medicinal Chemistry, 29(15), 2602–2616. https://doi.org/10.2174/0929867328666210914121324

Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023). Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduction and Targeted Therapy, 8(1), 375. https://doi.org/10.1038/s41392-023-01608-z

Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F. A., Topisirovic, I., & Hulea, L. (2019). mTOR as a central regulator of lifespan and aging. F1000Research, 8, F1000 Faculty Rev. https://doi.org/10.12688/f1000research.17196.1

Peralta-Garcia, A., Torrens-Fontanals, M., Stepniewski, T. M., Grau-Expósito, J., Perea, D., Ayinampudi, V., Waldhoer, M., Zimmermann, M., Buzón, M. J., Genescà, M., & Selent, J. (2021). Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. International Journal of Molecular Sciences, 22(24), 13592. https://doi.org/10.3390/ijms222413592

Perola, E., & Charifson, P. S. (2004). Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding. Journal of Medicinal Chemistry, 47(10), 2499–2510. https://doi.org/10.1021/jm030563w

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 | PNAS. (n.d.-a). Retrieved December 10, 2025, from https://www.pnas.org/doi/full/10.1073/pnas.1314124110

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 | PNAS. (n.d.-b). Retrieved December 28, 2025, from https://www.pnas.org/doi/10.1073/pnas.1314124110

Posansee, K., Liangruksa, M., Termsaithong, T., Saparpakorn, P., Hannongbua, S., Laomettachit, T., & Sutthibutpong, T. (2023). Combined Deep Learning and Molecular Modeling Techniques on the Virtual Screening of New mTOR Inhibitors from the Thai Mushroom Database. ACS Omega, 8(41), 38373–38385. https://doi.org/10.1021/acsomega.3c04827

Rampogu, S. (2023). A review on the use of machine learning techniques in monkeypox disease prediction. Science in One Health, 2, 100040. https://doi.org/10.1016/j.soh.2023.100040

Riniker, S., & Landrum, G. A. (2013). Open-source platform to benchmark fingerprints for ligand-based virtual screening. Journal of Cheminformatics, 5(1), 26. https://doi.org/10.1186/1758-2946-5-26

Ritchie, T. J., & Macdonald, S. J. F. (2009). The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discovery Today, 14(21–22), 1011–1020. https://doi.org/10.1016/j.drudis.2009.07.014

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011). mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery, 1(3), 248–259. https://doi.org/10.1158/2159-8290.CD-11-0085

Rogers, D., & Hahn, M. (2010). Extended-Connectivity Fingerprints. Journal of Chemical Information and Modeling, 50(5), 742–754. https://doi.org/10.1021/ci100050t

Roskoski, R. (2016). Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research, 103, 26–48. https://doi.org/10.1016/j.phrs.2015.10.021

Røsland, G. V., & Engelsen, A. S. T. (2015). Novel Points of Attack for Targeted Cancer Therapy. Basic & Clinical Pharmacology & Toxicology, 116(1), 9–18. https://doi.org/10.1111/bcpt.12313

Ross-Veitía, B. D., Palma-Ramírez, D., Arias-Gilart, R., Conde-García, R. E., Espinel-Hernández, A., Nuñez-Alvarez, J. R., Hernández-Herrera, H., & Llosas-Albuerne, Y. E. (2024). Machine learning regression algorithms to predict emissions from steam boilers. Heliyon, 10(5), e26892. https://doi.org/10.1016/j.heliyon.2024.e26892

Rozengurt, E. (2014). Mechanistic target of rapamycin (mTOR): A point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Frontiers in Physiology, 5. https://doi.org/10.3389/fphys.2014.00357

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Sánchez-Villaseñor, G., Pérez-Du Pond, E. A., Jasso-García, I., Vázquez-Sánchez, S. J., García-Romero, R. C., Gómez-Sierra, J. P., Castillo Cardiel, M. G., Álvarez-Villaseñor, A. S., Cervantes-Guevara, G., Cervantes-Pérez, E., Ramírez-Ochoa, S., González-Ojeda, A., & Fuentes-Orozco, C. (2025). Perfil clínico y factores de riesgo identificados en pacientes con cáncer renal en población mexicana. Actas Urológicas Españolas, 49(7), 501814. https://doi.org/10.1016/j.acuro.2025.501814

Saqib, U., Demaree, I. S., Obukhov, A. G., Baig, M. S., Ariel, A., & Hajela, K. (2024). The fate of drug discovery in academia; dumping in the publication landfill? Oncotarget, 15(1), 31–34. https://doi.org/10.18632/oncotarget.28552

Saxton, R. A., & Sabatini, D. M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell, 168(6), 960–976. https://doi.org/10.1016/j.cell.2017.02.004

Schmidt, R., Klein, R., & Rarey, M. (2022). Maximum Common Substructure Searching in Combinatorial Make-on-Demand Compound Spaces. Journal of Chemical Information and Modeling, 62(9), 2133–2150. https://doi.org/10.1021/acs.jcim.1c00640

Seger, C. A., & Miller, E. K. (2010). Category Learning in the Brain. Annual Review of Neuroscience, 33(1), 203–219. https://doi.org/10.1146/annurev.neuro.051508.135546

Seto, T., Nakane, S., Ji, L., Ueda, Y., Sugano, H., Takei, N., Kobayashi, M., Murayama, A., & Yamamoto, N. (2025). Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance. Lung Cancer, 203, 108478. https://doi.org/10.1016/j.lungcan.2025.108478

Shephard, E., Neal, R., Rose, P., Walter, F., & Hamilton, W. T. (2013). Clinical features of kidney cancer in primary care: A case-control study using primary care records. British Journal of General Practice, 63(609), e250–e255. https://doi.org/10.3399/bjgp13X665215

Shi, Y., Zhou, M., Kou, M., Zhang, K., Zhang, X., & Kong, X. (2023). Simultaneous quantitative chiral analysis of four isomers by ultraviolet photodissociation mass spectrometry and artificial neural network. Frontiers in Chemistry, 11, 1129671. https://doi.org/10.3389/fchem.2023.1129671

Syamsuddin, F., Damansyah, H., Harismayanti, H., Ahmad, S. N., Nurhaliza, S., & R. Taha, B. A. (2025). FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN CA MAMAE DI RSUD PROVINSI GORONTALO. The Shine Cahaya Dunia S-1 Keperawatan, 10(01). https://doi.org/10.35720/tscs1kep.v10i01.633

Sydow, D., Wichmann, M., Rodríguez-Guerra, J., Goldmann, D., Landrum, G., & Volkamer, A. (2019). TeachOpenCADD-KNIME: A Teaching Platform for Computer-Aided Drug Design Using KNIME Workflows. Journal of Chemical Information and Modeling, 59(10), 4083–4086. https://doi.org/10.1021/acs.jcim.9b00662

UNIVERSITAS GADJAH MADA
Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Targeting the PI3-kinase/Akt/mTOR signaling pathway—PubMed. (n.d.). Retrieved December 28, 2025, from https://pubmed.ncbi.nlm.nih.gov/24012393/

Tetko, I. V., & Clevert, D.-A. (2025). Advanced machine learning for innovative drug discovery. Journal of Cheminformatics, 17(1), 122, s13321-025-01061-w. https://doi.org/10.1186/s13321-025-01061-w

The roles of integrins in cancer—PubMed. (n.d.). Retrieved December 15, 2025, from https://pubmed.ncbi.nlm.nih.gov/34131655/

Tsaur, I., Makarević, J., Juengel, E., Gasser, M., Waaga-Gasser, A.-M., Kurosch, M., Reiter, M., Wedel, S., Bartsch, G., Haferkamp, A., Wiesner, C., & Blaheta, R. A. (2012). Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells. British Journal of Cancer, 107(5), 847–855. https://doi.org/10.1038/bjc.2012.313

Tuerkova, A., & Zdrazil, B. (2020). A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: Case studies for rare diseases and COVID-19. Journal of Cheminformatics, 12, 71. https://doi.org/10.1186/s13321-020-00474-z

Updating the Definition of Cancer | Molecular Cancer Research | American Association for Cancer Research. (n.d.). Retrieved December 15, 2025, from https://aacrjournals.org/mcr/article/21/11/1142/729785/Updating-the-Definition-of-CancerUpdating-the

Valdembri, D., & Serini, G. (2021). The roles of integrins in cancer. Faculty Reviews, 10, 45. https://doi.org/10.12703/r/10-45

Vogt, M., & Bajorath, J. (2013). Similarity Searching for Potent Compounds Using Feature Selection. Journal of Chemical Information and Modeling, 53(7), 1613–1619. https://doi.org/10.1021/ci4003206

Wagle, N., Grabiner, B. C., Allen, E. M. V., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., Ruan, D. T., Hanna, G. J., Haddad, R. I., Getz, G., Kwiatkowski, D. J., Carter, S. L., Sabatini, D. M., Jänne, P. A., Garraway, L. A., & Lorch, J. H. (2014). Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 371(15), 1426–1433. https://doi.org/10.1056/NEJMoa1403352

Wang, Y., Wang, X.-Y., Subjeck, J. R., Shrikant, P. A., & Kim, H. L. (2011). Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. British Journal of Cancer, 104(4), 643–652. https://doi.org/10.1038/bjc.2011.15

Warr, W. A. (2009). ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Journal of Computer-Aided Molecular Design, 23(4), 195–198. https://doi.org/10.1007/s10822-009-9260-9

Willett, P. (2006). Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today, 11(23–24), 1046–1053. https://doi.org/10.1016/j.drudis.2006.10.005

UNIVERSITAS
GADJAH MADA
**Pemanfaatan KNIME TeachOpenCADD dengan Integrasi Machine Learning dan Virtual Screening serta
Molecular Docking untuk Identifikasi Kandidat Inhibitor mTOR**
Akhmad Fauzan, apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.; Prof.Dr.rer.nat.apt. Adam Hermawan,M.Sc.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Williams, A. J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E. L., Evelo, C. T., Blomberg, N., Ecker, G., Goble, C., & Mons, B. (2012). Open PHACTS: Semantic interoperability for drug discovery. Drug Discovery Today, 17(21–22), 1188–1198. https://doi.org/10.1016/j.drudis.2012.05.016

Wullschleger, S., Loewith, R., & Hall, M. N. (2006). TOR Signaling in Growth and Metabolism. Cell, 124(3), 471–484. https://doi.org/10.1016/j.cell.2006.01.016

Xie, J., Wang, X., & Proud, C. G. (2016). mTOR inhibitors in cancer therapy. F1000Research, 5, F1000 Faculty Rev-2078. https://doi.org/10.12688/f1000research.9207.1

Yecies, J. L., Zhang, H. H., Menon, S., Liu, S., Yecies, D., Lipovsky, A. I., Gorgun, C., Kwiatkowski, D. J., Hotamisligil, G. S., Lee, C.-H., & Manning, B. D. (2011). Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways. Cell Metabolism, 14(1), 21–32. https://doi.org/10.1016/j.cmet.2011.06.002

Yellapu, N. K., Kandlapalli, K., Valasani, K. R., Sarma, P. V. G. K., & Matcha, B. (2013). Structural Variations of Human Glucokinase Glu256Lys in MODY2 Condition Using Molecular Dynamics Study. Biotechnology Research International, 2013, 1–9. https://doi.org/10.1155/2013/264793

Yin, Z., Song, Y., & Zong, G. (2024). Discovering API usage specifications for security detection using two-stage code mining. Cybersecurity, 7(1), 30. https://doi.org/10.1186/s42400-024-00224-w

Yoon, S.-O., Shin, S., Karreth, F. A., Buel, G. R., Jedrychowski, M. P., Plas, D. R., Dedhar, S., Gygi, S. P., Roux, P. P., Dephoure, N., & Blenis, J. (2017). Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Molecular Cell, 67(3), 512-527.e4. https://doi.org/10.1016/j.molcel.2017.06.033

Zanardi, E., Verzoni, E., Grassi, P., Necchi, A., Giannatempo, P., Raggi, D., De Braud, F., & Procopio, G. (2015). Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 7(3), 152–161. https://doi.org/10.1177/1756287215574457

Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., & Bray, F. (2015). International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality. European Urology, 67(3), 519–530. https://doi.org/10.1016/j.eururo.2014.10.002

Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., & Sabatini, D. M. (2011). mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (New York, N.Y.), 334(6056), 678–683. https://doi.org/10.1126/science.1207056

Zothantluanga, J. H., & Chetia, D. (2022). A Beginner's Guide to Molecular Docking. Sciences of Phytochemistry, 1(2), 90–93. https://doi.org/10.58920/sciphy01020037

Zou, Z., Tao, T., Li, H., & Zhu, X. (2020). mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell & Bioscience, 10(1), 31. https://doi.org/10.1186/s13578-020-00396-1